Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of iCF1, iCF2 and TF2 Formulations of BI 425809 in Healthy Subjects
NCT03817476Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iclepertin in schizophrenia (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 72 Hours and Maximum Measured Concentration of BI 425809 in Plasma at 72 hours. Started Feb 2019; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03817476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817476.